147 related articles for article (PubMed ID: 2842481)
1. Anti-EBV antibody titers in Italian patients with nasopharyngeal carcinoma.
Pirodda E; Caliceti U; Testoni S
J Exp Pathol; 1987; 3(4):479-83. PubMed ID: 2842481
[TBL] [Abstract][Full Text] [Related]
2. Nasopharyngeal carcinoma: the diagnostic value of the antibody-dependent, cellular cytotoxicity test and of EBV serology.
Faggioni A; Corradini C; Venanzoni M; Cardi G; Bevere F; Barile G; Zompetta C; Frati L
J Exp Pathol; 1987; 3(4):471-7. PubMed ID: 2842480
[TBL] [Abstract][Full Text] [Related]
3. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
[TBL] [Abstract][Full Text] [Related]
4. The reliability of IgA antibody to Epstein-Barr virus (EBV) capsid antigen as a test for the diagnosis of nasopharyngeal carcinoma (NPC).
Levine PH; Pearson GR; Armstrong M; Bengali Z; Berenberg J; Easton J; Goepfert H; Henle G; Henle W; Heffner D; Huang A; Hyams VJ; Lanier A; Neel HB; Pilch B; Pointek N; Taylor W; Terebelo H; Weiland L
Cancer Detect Prev; 1981; 4(1-4):307-12. PubMed ID: 6299561
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma (NPC).
Liu MT; Yeh CY
Radiat Med; 1998; 16(2):113-7. PubMed ID: 9650898
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of antibodies to Epstein-Barr virus in Italian patients with nasopharyngeal carcinoma.
Cevenini R; Donati M; Caliceti U; Moroni A; Tamba I; Rumpianesi F
J Infect; 1986 Mar; 12(2):127-31. PubMed ID: 3009628
[TBL] [Abstract][Full Text] [Related]
7. Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, tonsillar carcinoma and control groups.
Oberender H; Nowak R; Donner A; Kunkel M; Gärtner L; Scholtz HJ
Acta Virol; 1983 May; 27(3):277-81. PubMed ID: 6138990
[TBL] [Abstract][Full Text] [Related]
8. Analyses of the prognostic significance of the Epstein-Barr virus transactivator ZEBRA protein and diagnostic value of its two synthetic peptides in nasopharyngeal carcinoma.
Dardari R; Menezes J; Drouet E; Joab I; Benider A; Bakkali H; Kanouni L; Jouhadi H; Benjaafar N; El Gueddari B; Hassar M; Khyatti M
J Clin Virol; 2008 Feb; 41(2):96-103. PubMed ID: 18024156
[TBL] [Abstract][Full Text] [Related]
9. Serological and immunohistological assessment of Epstein-Barr virus infection in Sicilian patients with suspected nasopharyngeal carcinoma.
Ammatuna P; de Thè G; Speciale R; Sammartano F; Arista S; Zerillo G
Microbiologica; 1988 Apr; 11(2):89-94. PubMed ID: 2841559
[TBL] [Abstract][Full Text] [Related]
10. Comparison of three different serological techniques for primary diagnosis and monitoring of nasopharyngeal carcinoma in two age groups from Tunisia.
Karray H; Ayadi W; Fki L; Hammami A; Daoud J; Drira MM; Frikha M; Jlidi R; Middeldorp JM
J Med Virol; 2005 Apr; 75(4):593-602. PubMed ID: 15714486
[TBL] [Abstract][Full Text] [Related]
11. Serological markers in the diagnosis of histopathological types of nasopharyngeal carcinoma.
Sam CK; Prasad U; Pathmanathan R
Eur J Surg Oncol; 1989 Aug; 15(4):357-60. PubMed ID: 2547665
[TBL] [Abstract][Full Text] [Related]
12. Demonstration of Epstein-Barr virus-specific DNA polymerase in chemically induced Raji cells and its antibody in serum from patients with nasopharyngeal carcinoma.
Tan RS; Li JS; Grill SP; Nutter LM; Cheng YC
Cancer Res; 1986 Oct; 46(10):5024-8. PubMed ID: 3019519
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus serological markers for nasopharyngeal carcinoma in Thailand.
Puthavathana P; Sutthent R; Vitavasiri A; Wasi C; Chantarakul N; Thongcharoen P
Southeast Asian J Trop Med Public Health; 1991 Sep; 22(3):326-31. PubMed ID: 1818381
[TBL] [Abstract][Full Text] [Related]
14. Complementary serum test of antibodies to Epstein-Barr virus nuclear antigen-1 and early antigen: a possible alternative for primary screening of nasopharyngeal carcinoma.
Chang KP; Hsu CL; Chang YL; Tsang NM; Chen CK; Lee TJ; Tsao KC; Huang CG; Chang YS; Yu JS; Hao SP
Oral Oncol; 2008 Aug; 44(8):784-92. PubMed ID: 18206420
[TBL] [Abstract][Full Text] [Related]
15. [Value of anti-Epstein-Barr antibody detection in the diagnosis and management of undifferentiated carcinoma of the nasopharynx].
Mazeron MC
Bull Cancer Radiother; 1996; 83(1):3-7. PubMed ID: 8679277
[TBL] [Abstract][Full Text] [Related]
16. [Immunoglobulin A serum antibodies against the capsid antigen of Epstein-Barr virus in the differential diagnosis and follow-up of nasopharyngeal cancer].
Pavelka R; Popow-Kraupp T; Radaszkiewicz T
Wien Klin Wochenschr; 1985 Jul; 97(14):588-95. PubMed ID: 2996246
[TBL] [Abstract][Full Text] [Related]
17. Loss of heterozygosity and its correlation with clinical outcome and Epstein-Barr virus infection in nasopharyngeal carcinoma.
Shao JY; Huang XM; Yu XJ; Huang LX; Wu QL; Xia JC; Wang HY; Feng QS; Ren ZF; Ernberg I; Hu LF; Zeng YX
Anticancer Res; 2001; 21(4B):3021-9. PubMed ID: 11712805
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma.
Twu CW; Wang WY; Liang WM; Jan JS; Jiang RS; Chao J; Jin YT; Lin JC
Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):130-7. PubMed ID: 16979842
[TBL] [Abstract][Full Text] [Related]
19. [Rhinopharyngeal carcinoma and Epstein-Barr virus: study of a sample of Italian patients].
Caliceti U; Cevenini R; Donati M
Acta Otorhinolaryngol Ital; 1985; 5(1):83-90. PubMed ID: 2994355
[No Abstract] [Full Text] [Related]
20. Circulating immune complexes in patients with nasopharyngeal carcinoma.
Wolf GT; Wolfe RA
Laryngoscope; 1990 Mar; 100(3):302-8. PubMed ID: 1689798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]